Shares of BioScrip Inc (NASDAQ:BIOS) have been given a consensus recommendation of “Hold” by the nine analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $4.79.
A number of equities research analysts recently commented on BIOS shares. ValuEngine upgraded BioScrip from a “sell” rating to a “hold” rating in a research report on Monday, November 11th. SunTrust Banks increased their price target on shares of BioScrip from $3.25 to $4.25 and gave the stock a “buy” rating in a report on Friday, September 20th. Canaccord Genuity raised their price target on shares of BioScrip from $3.50 to $4.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Zacks Investment Research cut shares of BioScrip from a “hold” rating to a “sell” rating and set a $4.00 price objective for the company. in a research note on Monday, November 18th. Finally, BidaskClub downgraded shares of BioScrip from a “buy” rating to a “hold” rating in a report on Saturday, November 9th.
Shares of NASDAQ:BIOS traded up $0.21 during trading on Friday, hitting $3.07. The stock had a trading volume of 2,260,625 shares, compared to its average volume of 987,921. The company has a quick ratio of 1.36, a current ratio of 1.71 and a debt-to-equity ratio of 1.43. BioScrip has a 12-month low of $1.56 and a 12-month high of $4.14. The stock has a market capitalization of $2.20 billion, a price-to-earnings ratio of -6.27 and a beta of 0.44. The stock has a 50-day simple moving average of $3.43 and a two-hundred day simple moving average of $2.97.
Hedge funds have recently modified their holdings of the company. Venor Capital Management LP grew its holdings in BioScrip by 3.4% during the second quarter. Venor Capital Management LP now owns 12,333,605 shares of the company’s stock worth $32,067,000 after acquiring an additional 400,000 shares during the period. Gabelli Funds LLC increased its holdings in shares of BioScrip by 6.0% during the 2nd quarter. Gabelli Funds LLC now owns 7,168,041 shares of the company’s stock valued at $18,637,000 after purchasing an additional 407,422 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of BioScrip by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 6,551,808 shares of the company’s stock valued at $17,034,000 after purchasing an additional 332,385 shares in the last quarter. Rothschild & Co. Asset Management US Inc. lifted its stake in shares of BioScrip by 1.6% in the 2nd quarter. Rothschild & Co. Asset Management US Inc. now owns 3,874,113 shares of the company’s stock valued at $10,073,000 after purchasing an additional 61,642 shares during the period. Finally, Northern Trust Corp boosted its holdings in BioScrip by 2.4% during the second quarter. Northern Trust Corp now owns 1,486,282 shares of the company’s stock worth $3,864,000 after buying an additional 35,116 shares in the last quarter. 15.49% of the stock is owned by institutional investors and hedge funds.
BioScrip, Inc provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods.
See Also: Swap
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.